Knight Therapeutics (OTCMKTS:KHTRF) Stock Price Down 1.6%

Knight Therapeutics Inc. (OTCMKTS:KHTRF)’s stock price traded down 1.6% during trading on Thursday . The stock traded as low as $4.34 and last traded at $4.34. 100 shares traded hands during trading, a decline of 99% from the average session volume of 6,778 shares. The stock had previously closed at $4.41.

Wall Street Analysts Forecast Growth

Separately, Raymond James boosted their price objective on shares of Knight Therapeutics from $7.00 to $7.50 and gave the stock an “outperform” rating in a research note on Wednesday, March 6th.

Knight Therapeutics Stock Performance

The business’s 50 day simple moving average is $4.15 and its two-hundred day simple moving average is $4.04.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.